[1] 郑莹, 吴春晓, 张敏璐. 乳腺癌在中国的流行状况和疾病特征[J]. 中国癌症杂志, 2013,23(8):561-569. Zheng Y, Wu C X, Zhang M L. The prevalence and disease characteristics of breast cancer in China[J]. Chinese Journal of Cancer, 2013,23(8):561-569.
[2] Ogino K, Nakajima M, Kakuta M, et al. Utility of FDG-PET/CT in the evaluation of the response of locally advanced breast cancer to neoadjuvant chemotherapy[J]. International Surgery, 2014,99(4):309-318.
[3] 沈璐, 唐菲, 林翌, 等. 磁共振扩散加权成像ADC值对局部进展期乳腺癌新辅助化疗疗效及病理反应性的评估价值[J]. 临床和实验医学杂志, 2017,16(7):717-720. Shen L, Tang F, Lin Y, et al. The value of MR diffusion-weighted imaging ADC in evaluating the efficacy and patholo-gic response of neoadjuvant chemotherapy for locally advanced breast cancer[J]. Journal of Clinical and Experimental Medicine, 2017,16(7):717-720.
[4] 牛昀. 2012年版《WHO乳腺肿瘤分类》新变化与临床治疗的关系[J]. 中华乳腺病杂志(电子版), 2014,8(3):1-5. Niu Y. The relationship between the new changes of the WHO version of WHO breast tumor classification and clinical treatment in 2012[J]. Chinese Journal of Breast Diseases, 2014,8(3):1-5.
[5] Ogston K N, Miller I D, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J]. Breast, 2003,12(5):320-327.
[6] 郑荣寿, 孙可欣, 张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. Zheng R S, Sun K X, Zhang S W, et al. Report of cancer epidemiology in China, 2015[J].Chinese Journal of Oncology, 2019,41(1):19-28.
[7] Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients[J].Journal of Breast Cancer, 2014,17(4):376-385.
[8] Maforo N, Li H, Lan L, et al. SU-F-R-26:prognostic radiomics of breast cancer on DCE and DWI MR images[J]. Medical Physics, 2016,43(6Part6):3378-3378.
[9] 赵娓娓, 全志永, 陈燕, 等. DWI及ADC值在胃癌淋巴结性质判断及化疗疗效评估中的作用[J]. 放射学实践, 2015,30(5):566-570. Zhao W W, Quan Z Y, Chen Y, et al. The role of DWI and ADC values in the judgment of lymph node properties and eva-luation of chemotherapy efficacy in gastric cancer[J]. Radio-logy Practice, 2015,30(5):566-570.
[10] 朱振国, 姜熳. 核磁共振全身弥散加权成像(WB-DWI)在乳腺癌患者术前化疗疗效评估中的应用价值[J]. 肿瘤学杂志, 2016,22(6):443-447. Zhu Z G, Jiang M. The value of whole body diffusion-weighted imaging (WB-DWI) in the evaluation of preoperative chemotherapy in breast cancer patients[J].Journal of Oncology, 2016,22(6):443-447.
[11] 李向阳, 刘灵灵, 倪毅. 乳腺癌1.5T MRI动态增强扫描及DWI与免疫组化指标相关性分析[J]. 中国CT和MRI杂志, 2017,15(9):37-39. Li X Y, Liu L L, Ni Y. Dynamic contrast-enhanced scan of breast cancer with 1.5T MRI and correlation analysis between DWI and immunohistochemical markers[J]. Chinese Journal of CT and MRI, 2017,15(9):37-39.
[12] Kong D, Wang M H, Jie Y, et al. Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer[J]. Oncotarget, 2017,8(8):13747-13753.
[13] 宋萌萌, 张天月, 王丽君, 等. IVIM多参数预
[1] 测乳腺癌免疫组化指标表达的可行性研究[J]. 磁共振成像, 2017,8(3):170-175. Song M M, Zhang T Y, Wang L J, et al. Feasibility study of IVIM multi-parameter pre-
[1] measurement of breast cancer immunohistochemical markers[J]. Magnetic Resonance Imaging, 2017,8(3):170-175.
[14] 薛彩霞, 邱传亚, 张勇, 等. DWI和Vibrant动态增强MR成像在乳腺癌中的诊断价值[J]. 放射学实践, 2014,29(1):61-63. Xue C X, Qiu C Y, Zhang Y, et al. Diagnostic value of DWI and Vibrant dynamic enhanced MR imaging in breast cancer[J]. Radiology Practice, 2014,29(1):61-63.
[15] Debled M, Macgrogan G, Breton-Callu C, et al. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude[J].European Journal of Cancer, 2015,51(6):697-704. |